Discontinued — last reported Q1 '20
Amgen Finite-Lived Intangible Assets - Expected Amortization Expense (Year Five) remained flat by 0.0% to $2.30B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 4.5%, from $2.20B to $2.30B.
A trend of decreasing amortization indicates that the company's current intangible assets are nearing the end of their useful lives.
This represents the projected non-cash expense associated with the amortization of finite-lived intangible assets for th...
Commonly reported by large-cap pharmaceutical firms to provide visibility into long-term earnings quality.
finite_lived_intangible_assets_amortization_year_5| Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.80B | $1.10B | $1.10B | $1.10B | $2.20B | $2.20B | $2.20B | $2.20B | $2.30B | $2.30B |
| QoQ Change | — | -38.9% | +0.0% | +0.0% | +100.0% | +0.0% | +0.0% | +0.0% | +4.5% | +0.0% |
| YoY Change | — | — | — | -38.9% | +100.0% | +100.0% | +100.0% | +0.0% | +4.5% | +4.5% |
We use cookies for analytics. See our Privacy and Cookie Policy.